The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.

The goal of the trial is to see if the Safety and Tolerability of X/T+X/T-EC combined with currently treated Lecanemab participants with Alzheimer's Disease compared with placebo. This is a 32 week study (4 weeks of screening,24 weeks of treatment and 4 weeks of safety follow up)

NCT Number	NCT07212062
Lead Sponsor	Neurology Office of South Florida Collaborators: Bristol-Myers Squibb
Conditions	Alzheimers Disease
Enrollment	60 participants
Start Date	2025-12-01
Primary Completion	2028-04-01 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-10-08